Limits...
Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.

Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu XY, Gong LY - J. Exp. Clin. Cancer Res. (2012)

Bottom Line: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway.SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues.Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biochemistry and Molecular Biology, School of medicine, ShenZhen University, Shen Zhen, China.

ABSTRACT

Background: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway. The aim of this study was to describe the expression of SOX9 in human non-small cell lung cancer (NSCLC) and to investigate the association between SOX9 expression and progression of NSCLC.

Methods: SOX9 protein and mRNA expression in normal human pneumonocytes, lung cancer cell lines, and eight pairs of matched lung cancer tissues and their adjacent normal lung tissues were detected by Western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemistry was used to determine SOX9 protein expression in 142 cases of histologically characterized NSCLC. Statistical analyses were applied to test for prognostic and diagnostic associations.

Results: SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues. Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies. Statistical analysis indicated that upregulation of SOX9 was significantly correlated with the histological stage of NSCLC (P=0.017) and that patients with a high SOX9 level exhibited a shorter survival time (P<0.001). Multivariate analysis illustrated that SOX9 upregulation might be an independent prognostic indicator for the survival of patients with NSCLC.

Conclusions: This work shows that SOX9 may serve as a novel and prognostic marker for NSCLC, and play a role during the development and progression of the disease.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier analysis showing the overall survival of NSCLC patients categorized according to the AJCC grades and status of SOX9 expression. The statistical significance of the difference between curves of SOX9 high-expressing and low-expressing patients was compared within subgroups of AJCC grades I+II (A) and III+IV (B). P values were calculated by the log-rank test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3313873&req=5

Figure 5: Kaplan-Meier analysis showing the overall survival of NSCLC patients categorized according to the AJCC grades and status of SOX9 expression. The statistical significance of the difference between curves of SOX9 high-expressing and low-expressing patients was compared within subgroups of AJCC grades I+II (A) and III+IV (B). P values were calculated by the log-rank test.

Mentions: The prognostic value of SOX9 expression in different subgroups of NSCLC patients was stratified in relation to the histological staging. A significant correlation was found between high SOX9 expression and shorter overall survival time in AJCC-graded subgroups of NSCLC. Patients with tumors exhibiting high SOX9 expression had significantly shorter overall survival than those with low expression of SOX9 in either stages I + II subgroup (n = 43; P = 0.001, log-rank; Figure 5A) or stages III + IV subgroup (n = 56; P = 0.020, log-rank; Figure 5B), indicating that SOX9 could be a valuable prognostic marker for NSCLC patients at all disease stages.


Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.

Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu XY, Gong LY - J. Exp. Clin. Cancer Res. (2012)

Kaplan-Meier analysis showing the overall survival of NSCLC patients categorized according to the AJCC grades and status of SOX9 expression. The statistical significance of the difference between curves of SOX9 high-expressing and low-expressing patients was compared within subgroups of AJCC grades I+II (A) and III+IV (B). P values were calculated by the log-rank test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3313873&req=5

Figure 5: Kaplan-Meier analysis showing the overall survival of NSCLC patients categorized according to the AJCC grades and status of SOX9 expression. The statistical significance of the difference between curves of SOX9 high-expressing and low-expressing patients was compared within subgroups of AJCC grades I+II (A) and III+IV (B). P values were calculated by the log-rank test.
Mentions: The prognostic value of SOX9 expression in different subgroups of NSCLC patients was stratified in relation to the histological staging. A significant correlation was found between high SOX9 expression and shorter overall survival time in AJCC-graded subgroups of NSCLC. Patients with tumors exhibiting high SOX9 expression had significantly shorter overall survival than those with low expression of SOX9 in either stages I + II subgroup (n = 43; P = 0.001, log-rank; Figure 5A) or stages III + IV subgroup (n = 56; P = 0.020, log-rank; Figure 5B), indicating that SOX9 could be a valuable prognostic marker for NSCLC patients at all disease stages.

Bottom Line: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway.SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues.Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biochemistry and Molecular Biology, School of medicine, ShenZhen University, Shen Zhen, China.

ABSTRACT

Background: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway. The aim of this study was to describe the expression of SOX9 in human non-small cell lung cancer (NSCLC) and to investigate the association between SOX9 expression and progression of NSCLC.

Methods: SOX9 protein and mRNA expression in normal human pneumonocytes, lung cancer cell lines, and eight pairs of matched lung cancer tissues and their adjacent normal lung tissues were detected by Western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemistry was used to determine SOX9 protein expression in 142 cases of histologically characterized NSCLC. Statistical analyses were applied to test for prognostic and diagnostic associations.

Results: SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues. Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies. Statistical analysis indicated that upregulation of SOX9 was significantly correlated with the histological stage of NSCLC (P=0.017) and that patients with a high SOX9 level exhibited a shorter survival time (P<0.001). Multivariate analysis illustrated that SOX9 upregulation might be an independent prognostic indicator for the survival of patients with NSCLC.

Conclusions: This work shows that SOX9 may serve as a novel and prognostic marker for NSCLC, and play a role during the development and progression of the disease.

Show MeSH
Related in: MedlinePlus